Sight Sciences, Inc. Common Stock
SGHT Real Time Price USDRecent trades of SGHT by members of U.S. Congress
---
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in SGHT holdings by institutional investors
Quarterly net insider trading by SGHT's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More about Alpha -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More about Annual Standard Deviation -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More about Annual Volatility -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More about Beta -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More about CAGR -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More about Information Ratio -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More about Max Drawdown -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More about Sharpe Ratio -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More about Treynor Ratio -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
Former government officials who have lobbied for SGHT
11 former government officials from 8 congressional offices at 4 lobbying firms have lobbied for SGHT, most recently Apr 05, 2024.
-
Neal Patel Senate COS to Deputy Dir. for Mgmt., OMB (EOP); Dep. Assoc. Dir. for Leg Affairs, OMB (EOP); Professional Staff Member, Senate Finance Cmte; Comms Dir. & Counsel, Sen. Dean Heller; Comms Dir. & Counsel, Rep. Boustany, Jr.; Comms Dir., Rep. Wilson (SC) -
Luke Hatzis House New LD & LA, Cong. Peter Roskam; Republican Clerk, House Rules Committee; Legislative Aide, House Republican Conference; Floor Assistant, Speaker J. Dennis Hastert. -
Nick Bouknight House New Deputy Chief of Staff, Rep. Kevin McCarthy; Deputy Chief of Staff/ Communications Dir., Rep. Kevin McCarthy; Press Sec., Rep. Kevin McCarthy; Press Sec., Rep. Bill Thomas; Deputy Press Sec., Ways and Means Cmte.; Press Asst., Ways and Means Cmte. -
Martin Gold Senate New Floor Advisor & Counsel, Senate Majority Leader Bill Frist. -
Jeffrey Carroll House New Staff Director House Energy and Commerce Committee; Chief of Staff, Rep. Frank Pallone; Legislative Director, Rep. Frank Pallone; Legislative Assistant, Rep. Frank Pallone. -
Charles Boustany House New Former Member of Congress, Louisiana 7th and 3rd districts; House Ways and Means Committee.
-
Dwight Fettig Senate New Staff Director, Senate Committee on Banking, Housing, and Urban Affairs
-
Jeremy Rabinovitz House New Legislative Assistant and Chief of Staff, Rep. Solarz; Chief of Staff, Rep. Maloney; Chief of Staff, Rep. Walter Capps; Chief of Staff, Rep. Lois Capps
SGHT Estimated quarterly lobbying spending
SGHT Revenue by Segment or Geography
New SGHT patent grants
-
Patent Title: Devices and methods for intraocular tissue manipulation Sep. 22, 2026
-
Patent Title: Ocular delivery systems and methods Sep. 22, 2026
-
Patent Title: Treatment apparatus and methods Sep. 22, 2026
-
Patent Title: Intraocular devices, systems, and methods Mar. 31, 2026
-
Patent Title: Ocular delivery systems and methods Mar. 31, 2026
-
Patent Title: Intraocular implants and methods and kits therefor Feb. 17, 2026
-
Patent Title: Ocular delivery systems and methods Jul. 08, 2025
-
Patent Title: Dry eye treatment apparatus and methods Jun. 24, 2025
-
Patent Title: Devices and methods for intraocular tissue manipulation May. 27, 2025
-
Patent Title: Dry eye treatment systems Apr. 01, 2025
-
Patent Title: Forceps treatment systems Apr. 01, 2025
-
Patent Title: Controller for dry eye treatment systems Mar. 25, 2025
-
Patent Title: Ocular delivery systems and methods Feb. 04, 2025
-
Patent Title: Intraocular implants and related kits and methods Dec. 24, 2024
-
Patent Title: Ocular delivery systems and methods Oct. 29, 2024
-
Patent Title: Ocular delivery systems and methods Oct. 29, 2024
-
Patent Title: Ocular delivery systems and methods Jul. 23, 2024
-
Patent Title: Ocular delivery systems and methods Apr. 09, 2024
-
Patent Title: Formulations and methods for treating conditions of the eye Mar. 12, 2024
-
Patent Title: Devices and methods for intraocular tissue manipulation Jan. 23, 2024
-
Patent Title: Ocular delivery systems and methods Jan. 16, 2024
-
Patent Title: Intraocular implants and methods and kits therefor Jan. 09, 2024
-
Patent Title: Ocular delivery systems and methods Jan. 02, 2024
-
Patent Title: Ocular delivery systems and methods Apr. 04, 2023
-
Patent Title: Formulations and methods for treating conditions of the eye Jan. 17, 2023
-
Patent Title: Ocular delivery systems and methods Nov. 22, 2022
-
Patent Title: Ocular delivery systems and methods Oct. 18, 2022
-
Patent Title: Formulations and methods for treating conditions of the eye Aug. 23, 2022
-
Patent Title: Intraocular implants and methods and kits therefor Jul. 19, 2022
-
Patent Title: Ocular delivery systems and methods Jul. 19, 2022
-
Patent Title: Ocular delivery systems and methods May. 31, 2022
-
Patent Title: Combination treatment systems Mar. 29, 2022
-
Patent Title: Intraocular implants and related kits and methods Nov. 09, 2021
-
Patent Title: Ocular delivery systems and methods Sep. 14, 2021
-
Patent Title: Ocular delivery systems and methods Feb. 20, 2018
-
Patent Title: Ocular delivery systems and methods Jan. 02, 2018
-
Patent Title: Dry eye treatment systems Dec. 19, 2017
-
Patent Title: Dry eye treatment apparatus and methods Aug. 08, 2017
-
Patent Title: Methods for improving contact lens comfort May. 09, 2017
-
Patent Title: Dry eye treatment systems Dec. 06, 2016
-
Patent Title: Intraocular implants and methods and kits therefor Nov. 08, 2016
-
Patent Title: Intraocular implants and methods and kits therefor Jun. 21, 2016
-
Patent Title: Ocular delivery systems and methods Dec. 22, 2015
-
Patent Title: Ocular delivery systems and methods Aug. 04, 2015
-
Patent Title: Ocular delivery systems and methods Nov. 25, 2014
-
Patent Title: Intraocular implants and related kits and methods Nov. 04, 2014
-
Patent Title: Intraocular implants and related kits and methods Sep. 10, 2013
-
Patent Title: Intraocular implants and related kits and methods May. 14, 2013
-
Patent Title: Intraocular implants and methods and kits therefor Oct. 16, 2012
-
Patent Title: Intraocular implants and methods and kits therefor Mar. 22, 2011
Federal grants, loans, and purchases
Estimated quarterly amount awarded to SGHT from public contracts
Recent insights relating to SGHT
Recent picks made for SGHT stock on CNBC
ETFs with the largest estimated holdings in SGHT
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $SGHT stock a Buy, Sell, or Hold?
- What is the price target for $SGHT stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $SGHT stock?
- Who owns the most shares of $SGHT stock?
- What funds own $SGHT stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view SGHT Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.
- Address Menlo Park, CA
- Market Cap 469.9 million
- Employees 186
- Industrial Classification Surgical & Medical Instruments & Apparatus
Sight Sciences, Inc. Common Stock (SGHT) Historical Stock Prices
Daily open, high, low, close, adjusted close and volume for Sight Sciences, Inc. Common Stock (SGHT).
Quiver Premium charts SGHT's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.
Upgrade to Premium| Date | Open | High | Low | Close | Adj. Close | Volume |
|---|
Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.
The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.
Explore the Quiver APIWe estimate that -- received a compensation of -- in --, making them the highest paid executive at SGHT, per a recent SEC DEF 14A filing.
|
Name
|
Role
|
Salary
|
Bonus
|
Stock/Option Awards
|
Total Compensation
|
|---|